Real-World Patient and Treatment Characteristics in Children Under 4 Years Old with DMD Receiving the Exon-Skipping Therapy, Viltolarsen - NSPharma
Who We Are
Leadership
Partnership
Our Science
Therapeutic Areas
Duchenne
Hunter Syndrome
EGPA
Scientific Approach
Exon-Skipping
Gene Therapy
Selective JAK1 Inhibition
Pipeline & Products
Products
Clinical Trials
Newsroom
Events & Posters
Press Releases
Careers
Our Culture
Contact Us
Real-World Patient and Treatment Characteristics in Children Under 4 Years Old with DMD Receiving the Exon-Skipping Therapy, Viltolarsen
View PDF
Back to Press Releases
